Riya Malhotra, a 34-year-old marketing manager based in Gurugram, describes her days as oddly flat since starting Mounjaro. Meals no longer anchor her routine. Lunch decisions feel mechanical rather than driven by hunger.
Foods Riya once enjoyed now seem interchangeable. She reports eating because she “should”, not because she wants to. The absence of cravings initially felt liberating. Over time, it has begun to feel like a low-grade indifference towards food itself.
Clinicians are increasingly hearing similar accounts. Women using GLP-1 receptor agonists, particularly Mounjaro, report a muted relationship with eating. The effect is not dramatic fatigue or depression. It is a quieter flattening of food-related motivation, with daily meals seeming like tasks to complete.
The science behind this effect is relatively clear. Mounjaro acts on both GLP-1 and GIP pathways, influencing insulin secretion, gastric emptying and satiety signals. The drug slows down how quickly the stomach empties, prolonging fullness after small meals. At the same time, it affects reward circuitry in the brain. Dopamine-linked responses to food cues are dampened. Cravings are reduced, not just physically but neurologically. The brain registers less excitement around eating, which can translate into emotional neutrality towards food.
For many patients, this is precisely the intended benefit. Reduced cravings can help break cycles of overeating and improve metabolic outcomes. However, the same mechanism can create a practical challenge. When hunger cues weaken, decision-making around meals becomes less intuitive. Some users report standing in kitchens without clear preferences. Others default to repetitive, simplified meals because variety no longer feels rewarding.
Ananya Sen Gupta, a 41-year-old school teacher based in Kolkata, notes that her grocery habits have changed significantly. She now buys fewer impulse items and more staples. While this has improved her diet quality, she admits that planning meals requires conscious effort. Neha Kapoor, a 29-year-old fashion stylist based in Mumbai, reports skipping meals unintentionally because she “forgets to feel hungry.” She has since begun setting reminders to eat balanced portions across the day.
Experts suggest that this “meh” phase is not harmful in itself, but requires adjustment. Structured eating plans can help restore rhythm. Protein-focused meals, consistent timing and pre-planned menus reduce the cognitive load of deciding what to eat. Some patients also reframe meals as functional rather than emotional, focusing on nourishment rather than enjoyment.
Importantly, this shift does not indicate that the medication is damaging overall well-being. Weight loss, improved glycaemic control and reduced metabolic risk remain well-documented benefits of Mounjaro. The emotional flattening around food is better understood as a byproduct of appetite regulation, not a broader suppression of mood.
There is also a growing need to address misconceptions. Social media narratives often frame the loss of food interest as either a miracle or a problem. According to Dr Jasjeet Wasir, head of endocrinology at Medanta Hospital, Gurugram, “Mounjaro myths require to be fact-checked by doctors.” He emphasises that patient experiences vary widely and should be interpreted in a clinical context, not through anecdotal extremes.
As more users adapt to these medications, the conversation is shifting from weight loss alone to lived experience. The “meh” effect may persist for some, ease for others or simply become the new normal. What remains consistent is the need for guidance. With structured habits and medical oversight, the flattening of cravings can be managed without compromising overall health.
Subscribe to India Today Magazine
– Ends
